Analysis Tools
immune system
|
• in vitro, purified mutant B cells display reduced up-regulation of various surface molecules, including CD23, CD54, CD80, CD86 and Fas, in response to stimulation with agonistic anti-CD40 mAb
• proliferative responses of mutant purified B cells to anti-CD40, CD40 ligand, and anti-CD40 plus anti-IgM are significantly reduced relative to those of wild-type B cells; addition of IL-4 partially restores the response
• in contrast, proliferative responses of mutant B cells to IL-4, anti-IgM, or LPS are similar to those of wild-type B cells, indicating a a specific defect in CD40-mediated activation
• however, when mutant splenocytes or purified B cells are stimulated with anti-CD40 mAb, the activation of NF-kappaB or JNK/SAPK by CD40 is not significantly altered relative to similarly-treated wild-type B cells
|
|
• in vitro, homozygous mutant thymocytes display consistently lower proliferative responses than wild-type thymocytes when stimulated with anti-CD3 mAb in the presence of irradiated CD70-transfected murine mastcytoma P815 (CD70-P815), indicating that CD27-mediated costimulation is impaired
• in contrast, stimulation with anti-CD3 mAb in the presence of irradiated P815 or CD80-P815 enhances proliferation of homozygous mutant and wild-type thymocytes to a similar extent
• surprisingly, when mutant thymocytes are stimulated with agonistic anti-CD27 mAb followed by goat anti-hamster Igs, the activation of either NF-kappaB or JNK/SAPK by CD27 is not significantly altered relative to similarly-treated wild-type thymocytes
|
|
• in vivo, homozygotes exhibit a mild defect in affinity maturation of IgG1 antibodies to a T-dependent antigen (NP22-CG)
|
|
• when purified mutant B cells are stimulated with anti-CD40 plus IL-4, in vitro production of IgG1 is significantly reduced relative to similarly-treated wild-type B cells
|
|
• when purified mutant B cells are stimulated with anti-CD40 plus IL-4, in vitro production of IgM is significantly reduced relative to similarly-treated wild-type B cells
|
hematopoietic system
|
• in vitro, purified mutant B cells display reduced up-regulation of various surface molecules, including CD23, CD54, CD80, CD86 and Fas, in response to stimulation with agonistic anti-CD40 mAb
• proliferative responses of mutant purified B cells to anti-CD40, CD40 ligand, and anti-CD40 plus anti-IgM are significantly reduced relative to those of wild-type B cells; addition of IL-4 partially restores the response
• in contrast, proliferative responses of mutant B cells to IL-4, anti-IgM, or LPS are similar to those of wild-type B cells, indicating a a specific defect in CD40-mediated activation
• however, when mutant splenocytes or purified B cells are stimulated with anti-CD40 mAb, the activation of NF-kappaB or JNK/SAPK by CD40 is not significantly altered relative to similarly-treated wild-type B cells
|
|
• in vitro, homozygous mutant thymocytes display consistently lower proliferative responses than wild-type thymocytes when stimulated with anti-CD3 mAb in the presence of irradiated CD70-transfected murine mastcytoma P815 (CD70-P815), indicating that CD27-mediated costimulation is impaired
• in contrast, stimulation with anti-CD3 mAb in the presence of irradiated P815 or CD80-P815 enhances proliferation of homozygous mutant and wild-type thymocytes to a similar extent
• surprisingly, when mutant thymocytes are stimulated with agonistic anti-CD27 mAb followed by goat anti-hamster Igs, the activation of either NF-kappaB or JNK/SAPK by CD27 is not significantly altered relative to similarly-treated wild-type thymocytes
|
|
• when purified mutant B cells are stimulated with anti-CD40 plus IL-4, in vitro production of IgG1 is significantly reduced relative to similarly-treated wild-type B cells
|
|
• when purified mutant B cells are stimulated with anti-CD40 plus IL-4, in vitro production of IgM is significantly reduced relative to similarly-treated wild-type B cells
|
cellular
|
• in vitro, purified mutant B cells display reduced up-regulation of various surface molecules, including CD23, CD54, CD80, CD86 and Fas, in response to stimulation with agonistic anti-CD40 mAb
• proliferative responses of mutant purified B cells to anti-CD40, CD40 ligand, and anti-CD40 plus anti-IgM are significantly reduced relative to those of wild-type B cells; addition of IL-4 partially restores the response
• in contrast, proliferative responses of mutant B cells to IL-4, anti-IgM, or LPS are similar to those of wild-type B cells, indicating a a specific defect in CD40-mediated activation
• however, when mutant splenocytes or purified B cells are stimulated with anti-CD40 mAb, the activation of NF-kappaB or JNK/SAPK by CD40 is not significantly altered relative to similarly-treated wild-type B cells
|
|
• in vitro, homozygous mutant thymocytes display consistently lower proliferative responses than wild-type thymocytes when stimulated with anti-CD3 mAb in the presence of irradiated CD70-transfected murine mastcytoma P815 (CD70-P815), indicating that CD27-mediated costimulation is impaired
• in contrast, stimulation with anti-CD3 mAb in the presence of irradiated P815 or CD80-P815 enhances proliferation of homozygous mutant and wild-type thymocytes to a similar extent
• surprisingly, when mutant thymocytes are stimulated with agonistic anti-CD27 mAb followed by goat anti-hamster Igs, the activation of either NF-kappaB or JNK/SAPK by CD27 is not significantly altered relative to similarly-treated wild-type thymocytes
|
